Engflag

Oprimea

Quick links to important sections

Oprimea

Selected form

Oprimea_IT

Method of action: Antiparkinsonian, Dopaminergic

Treatment option: Parkinson Disease, Restless Legs Syndrome

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oprimea

Oprimea: Quick Facts

Property Description
Active Ingredient Pramipexole (as Oprimea-alpha INN)
Form Modified-Release Tablet
Pharmacological Class Non-Ergot Dopamine Agonist
Origin Synthetic Compound
General Purpose Supports motor control and systemic regulation

What Type of Medicine is Oprimea?

Oprimea is a prescription medication chemically classified as a Non-Ergot Dopamine Agonist. It contains the active ingredient pramipexole, an International Nonproprietary Name (INN) compound. This pharmacological classification is clinically recognized for selectively activating certain dopamine receptors in the central nervous system. This supports Oprimea's specific role in modulating brain signals that influence movement and coordination.

The active ingredient is a synthetic compound, which allows for strict control over its composition and ensures high purity across all manufactured batches. Oprimea is often differentiated within its class by its preference for the D3 receptor subtype. This targeted profile is a key aspect of the medicine's design.

What is Oprimea Designed to Do?

The primary goal of Oprimea is to provide consistent, sustained support for key systems that regulate movement and sensory discomfort. It is formulated as a modified-release tablet for oral administration, a feature that sets it apart from immediate-release generic forms of pramipexole. The prolonged-release dosage form is specifically engineered to maintain stable drug levels in the bloodstream, which is beneficial for managing chronic conditions and simplifying dosing schedules. This specialized drug delivery system is intended to provide stable therapeutic support with reduced fluctuations in activity throughout the day.

By focusing on regulatory support, Oprimea is commonly used in therapeutic scenarios requiring long-term functional stability, such as controlling involuntary movements or easing symptoms of sensory discomfort that typically worsen during periods of rest.

Regulatory References

  1. EMA Mirapexin (Pramipexole) EPAR

What side effects are possible with Oprimea?

Possible Side Effects and Safety Information

The safety profile of Oprimea (pramipexole) is formally documented in government regulatory labeling, categorizing potential adverse reactions based on incidence and physiological system affected.

Frequency-Classified Adverse Reactions

The following are examples of adverse reactions reported in clinical trials, classified according to frequency in official regulatory documents:

Classification Examples of Documented Reactions
Very Common (>1/10 patients) Nausea, Somnolence (sleepiness), Dizziness, Dyskinesia
Common (≥1/100 to <1/10 patients) Constipation, Fatigue, Hallucinations, Headache, Insomnia, Peripheral edema

These effects are grouped by System-Organ Classes (SOC), primarily affecting the Nervous System (e.g., Somnolence, Dyskinesia), Gastrointestinal System (e.g., Nausea, Constipation), and Psychiatric Disorders (e.g., Hallucinations).

Serious Adverse Reactions and Safety Constraints

Official labeling highlights specific, serious adverse reactions. These include the potential for Falling Asleep During Activities of Daily Living (sudden sleep attacks), the development of Impulse Control and Compulsive Behaviors (e.g., pathological gambling, hypersexuality), and Symptomatic Orthostatic Hypotension (a drop in blood pressure upon standing).

Time-Related Patterns are noted, such as the need for monitoring Orthostatic Hypotension during dose escalation and that somnolence may appear long after treatment initiation. Safety Constraints include the restriction against use in cases of known Hypersensitivity and warnings against abrupt withdrawal, which may lead to a withdrawal-emergent syndrome. Population-specific considerations state that the risk of Hallucinations is increased in Older Adults, and patients with Renal Impairment require a dose reduction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

Documented overdose presentations: Overdose manifestations primarily reflect excessive dopaminergic activity, leading to Hypotension (low blood pressure), including significant Orthostatic Hypotension, and severe Somnolence or profound drowsiness. Other documented CNS effects include Visual Hallucinations and potential exacerbation of motor control difficulties.

Physiological systems affected (as stated in label): The official label indicates effects on the Cardiovascular system (hypotension, fast heart rate) and the Central Nervous System (altered mental status, sedation).

Dose-related or exposure-related factors (if applicable): Toxicity effects are related to plasma concentrations exceeding the therapeutic range, particularly due to the drug's near-exclusive renal elimination.

Population-specific overdose notes (if applicable): Patients with Renal Impairment are at risk for increased and prolonged overdose effects. Elderly patients are also documented as being more susceptible to severe CNS manifestations, such as hallucinations.

Emergency-response statements (as written in official documents): Seek immediate medical attention for any suspected overdose. The required action is to call emergency services or contact a Poison Control center if severe symptoms such as collapse, trouble breathing, or seizure occur.

When immediate medical help is required (label-derived phrasing only): Immediate help is required upon suspected overdose or the occurrence of severe symptoms including fast heart rate or an inability to be awakened.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Overdose is classified as an acute condition requiring emergency medical attention due to the potential for serious cardiovascular and neurological instability.

Regulatory basis (EMA / FDA / etc.): This information is consistent with regulatory documents such as the FDA Prescribing Information and EMA Summary of Product Characteristics.

Overdose-context constraints (as defined in official documents): No specific antidote is known for pramipexole. Hemodialysis is not an effective measure.

Resulting Overdose Structure

Official overdose statements:

  • Overdose manifests as hypotension and exaggerated CNS effects, including severe somnolence and hallucinations.
  • Immediate medical attention and contact with emergency services or Poison Control are mandatory for suspected overdose.
  • No specific antidote is known; treatment must be symptomatic and supportive.
  • Official guidance mandates monitoring of vital signs and cardiovascular status.
  • Effects are expected to be prolonged in patients with impaired renal function.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Oprimea overdose profile through the presentation of acute, exaggerated dopamine agonist effects, prominently featuring cardiovascular instability and severe neurological symptoms. This necessitates a strictly mandated, immediate emergency response—contacting emergency services—due to the potential severity of symptoms and the documented lack of a specific pharmacological antidote. The management strategy described in regulatory labels is limited to observation and supportive measures tailored to the patient’s documented clinical presentation.

Therapeutic Uses of Oprimea

What Oprimea Treats: Main Uses and Benefits

Oprimea is a prescription medication commonly used to help with conditions presenting with symptoms of increased neurological or muscular activity, specifically Idiopathic Parkinson's Disease (PD) and Restless Legs Syndrome (RLS). The medicine is utilized for conditions that present with systemic or localized discomfort associated with these diagnoses.

In Idiopathic Parkinson's Disease, Oprimea is applied to address fundamental movement difficulties, helping to manage symptom clusters such as tremor, rigidity, and bradykinesia. The treatment may assist with maintaining functional stability and supports the handling of distressing manifestations.

For Restless Legs Syndrome, the medication is relevant for easing the unpleasant sensory discomfort and the associated irresistible urge to move that characteristically intensifies during periods of rest. This treatment may assist with improving day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Motor and Sensory Symptoms
Oprimea plays a role in managing symptoms related to both impaired movement control and nocturnal sensory discomfort, supporting the patient during difficult episodes by easing distress.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Oprimea? — Official Regulatory Information

This medicine's eligibility is determined by official regulatory criteria, primarily based on hypersensitivity, age, and renal function. It is generally intended for adults (18 years and older).

Populations and Use Status

Population Group Regulatory Status
Hypersensitivity Contraindicated
Children/Adolescents (under 18 years) Not Recommended
Severe Renal Impairment Not Recommended
Pregnant/Lactating Women Restricted Use

Eligibility Constraints and Exclusions

The medicine is contraindicated and must not be used by any patient with a known hypersensitivity (allergic reaction) to the active substance, pramipexole, or any other ingredient in the formulation.

Use is not recommended in children and adolescents below 18 years due to a lack of established safety and efficacy data. For those with renal impairment, dose adjustments are required based on creatinine clearance, and use is not recommended for patients with severe impairment or those on hemodialysis. Use during pregnancy is advised only if the benefit clearly outweighs the potential risk to the fetus, and use during lactation requires discontinuation of breast-feeding.

What should I know about interactions with other medicines?

Oprimea Interactions with other medicines and products (Official Regulatory Summary)

This section outlines interactions with Oprimea (pramipexole) strictly as documented in official government regulatory sources, such as the FDA and EMA.

Pharmacokinetic Interactions (Clearance)

Interaction Type Interacting Substances/Context Official Statement
Reduced Clearance Cimetidine and other medicines eliminated by the active renal elimination pathway (e.g., amantadine, mexiletine, quinine). These substances may inhibit the renal cationic secretory transport system, resulting in reduced clearance of Oprimea and potentially increased exposure.
Metabolic Pathway CYP enzymes Oprimea undergoes little biotransformation; clinically significant interactions based on CYP-mediated metabolism are unlikely.

Pharmacodynamic Interactions

Interaction Type Interacting Substances/Context Official Statement
Additive Effects Alcohol and other sedating medicinal products (e.g., CNS depressants). Use with alcohol should be avoided due to the increased risk of drowsiness. Caution is advised with sedating medicines due to potential additive effects of somnolence.
Antagonistic Effects Dopamine antagonists (including most antipsychotic medicinal products). Co-administration may diminish the effectiveness of Oprimea and is generally avoided.
Dyskinesia Risk Levodopa Concomitant use increases the risk of dyskinesia; a reduction in the Levodopa dose is recommended.

Population and Administration Constraints

Interactions may be more significant in patients with renal impairment, as Oprimea's elimination is dependent on renal function. Oprimea may be taken with or without food.

Mechanism of Action

How Oprimea Works

Oprimea functions primarily by selectively and non-competitively inhibiting Farnesyl Pyrophosphate Synthase (FPPS), a key enzyme within the mevalonate pathway. This initial molecular action prevents the synthesis of essential prenyl lipids, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).

This inhibition of prenylation leads to a downstream mechanistic cascade where small signaling proteins, such as GTPases (like Ras and Rho), are prevented from anchoring to the cellular membrane. The lack of proper membrane localization effectively inactivates these signaling proteins. Consequently, the intracellular signaling pathways regulated by these GTPases are significantly modulated, leading to reduced cell motility and survival.

At the system-level, the consequence of this targeted inhibition and subsequent disruption of GTPase signaling is a physiological change characterized by modulated cellular proliferation and reduced activity in specific cell types critical to immune and structural functions.

Dosage and Administration Information

How to Use Oprimea

Oprimea is a modified-release tablet containing pramipexole, a formulation specifically designed for once daily oral administration. The tablet must be swallowed whole and must not be crushed, chewed, or divided, as this would compromise the prolonged drug release mechanism. The medication can be taken with or without food but should be taken consistently at about the same time each day.

Standard Dosage and Titration

For the treatment of idiopathic Parkinson's disease, therapy is initiated at a low, standardized starting dose of 0.375 mg once daily. The dose is gradually increased, or titrated, in increments of 0.375 mg or 0.75 mg no more frequently than every 5 to 7 days, until the appropriate maintenance dose is achieved. The highest recommended daily dose for this modified-release formulation is 4.5 mg per day. The modified-release tablets are not indicated for the management of Restless Legs Syndrome, an indication restricted to the immediate-release formulation.

Special Administration Guidance

If a dose of Oprimea is missed, the dose should be taken as soon as possible, but no later than 12 hours after the regularly scheduled time. If more than 12 hours have elapsed, the missed dose should be skipped.

In patients with moderate renal impairment (creatinine clearance 30 -50 mL/min), a modified starting regimen of 0.375 mg every other day is used, and the maximum daily dose is limited to 2.25 mg. Treatment cessation should always involve gradual dose reduction (tapering) to prevent the development of specific symptoms.

Recent Clinical Evidence

Research evidence / Overview of studies for Oprimea

Evidence for use in Idiopathic Parkinson's Disease (PD)

The research evidence relating to pramipexole, the active ingredient in Oprimea, in Parkinson's disease is primarily based on Randomized Controlled Trials (RCTs). These are short-term, tightly controlled studies that compare the active compound against a non-active placebo. Researchers studied how symptoms change over time, applying the compound in trials for two main groups: adults with Early PD (monotherapy) and those with Advanced PD (as add-on therapy).

In these studies, researchers monitored changes in motor function using validated scales, such as the UPDRS, to measure outcomes related to the ability to perform daily activities, including tremor and rigidity. In advanced disease, research examined patient-reported outcomes describing "On" time (periods of higher motor control) and "Off" time (periods of lower motor control) to see how symptoms evolved.

Evidence for use in Moderate-to-Severe Restless Legs Syndrome (RLS)

Oprimea was studied for Restless Legs Syndrome (RLS) primarily in short-term, placebo-controlled RCTs. Research explored short-term symptom changes, specifically the patient-reported sensory discomfort and the associated urge to move that characterize the condition. The main measurements were evaluated in trials using validated scales, such as the IRLS, and some studies also monitored objective movement measures, like the Periodic Limb Movement Index (PLMI), to assess episodic changes in leg movements during sleep.

Evidence Gaps and Areas for Ongoing Research

The most extensive controlled research focused on short-term outcomes. Evidence from highly controlled trials is limited regarding outcomes over many years, with much of the long-term follow-up observed in some studies being less controlled open-label extension studies. A key area of uncertainty is whether the compound was observed to change the underlying progression of Parkinson's disease. Additionally, the certainty remains low regarding the long-term management of potential augmentation in RLS, which refers to the research category related to symptom worsening over time.

Frequently Asked Questions (FAQ)

Common questions about Oprimea (FAQ)

Q: Can I take this medication with my morning cup of coffee?

Official product information specifies whether Oprimea should be taken with food or on an empty stomach. If the regulatory text does not contain a specific warning about caffeine or coffee, one should refer to the instructions regarding general food intake (e.g., 'may be taken without regard to meals').

Q: Does this drug cause sleepiness, making it unsafe to drive?

The official product information addresses the potential for Oprimea to affect the ability to drive or use machinery. Regulatory documents list somnolence or drowsiness as potential side effects. These sources include a specific warning if the medication is known to influence mental alertness.

Q: Is this medication safe for children aged 5 years old?

Regulatory documents define the age groups and conditions for which Oprimea is authorized. The official information only describes approved uses and dosing for specific age groups. If a dose or use for children aged 5 years is not described in the approved prescribing information, its use is not officially authorized or described.

Q: What is the correct way to store this medicine?

Regulatory documents explicitly state the required storage conditions for Oprimea. Official documents specify the required storage conditions, such as the exact temperature range or need for protection from light or moisture, to ensure the medicine retains its intended quality.

Q: Will this drug interact with my blood pressure medication?

The official product labeling for Oprimea includes a dedicated section on potential Drug Interactions. This section details known or clinically significant interactions between Oprimea and other medicines, which may include classes of medications such as those used for blood pressure.

How should Oprimea be stored and disposed of?

The official regulatory documents provide clear mandates for the storage and final disposal of Oprimea to ensure the stability of the modified-release formulation and to protect public safety.

Storage Component Regulatory Requirement
Temperature Store at room temperature, away from excess heat. Keep the medication from freezing
Protection Keep in the original container, tightly closed, protected from light and moisture.
Child Safety Keep out of the sight and reach of children in a secure location.
Disposal Do not discard into household waste or wastewater. Dispose of any unused or expired product according to local regulations, such as by returning it to a pharmacist or designated take-back site.

These constraints define how Oprimea must be secured and protected: it must be maintained under controlled room temperature conditions, safeguarded from environmental factors like light, and secured from accidental ingestion by children. Disposal must follow explicit regulatory procedures for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Oprimea found in:

A-Z Index: